Clinical trials: Adjustment
Parenting Practices, Self Efficacy
Talk Parenting Education Program II
The goal of this clinical trial is to learn whether Talk Parenting, a voice-based program delivered through an Amazon Echo Dot (Alexa), can help parents and caregivers of children ages 3-5 years improve challenging bedtime and…
- Conditions
- Parenting Practices, Self Efficacy, Stress, Child Behavior
- Trial name
- TP2 (NCT07462052)
- Testing
- The Talk Parenting Program
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis.
- Conditions
- Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia
- Trial name
- NCT07072728
- Testing
- Psilocybin therapy
- Where
- 3 sites in Australia
- Volunteers
- 87 people
- Sponsor
- Psyence Australia Pty Ltd
Adjustment Disorder With Anxious Mood
PH94B in the Treatment of Adjustment Disorder With Anxiety
This placebo-controlled clinical study is designed to evaluate the efficacy, safety and tolerability of administration of PH94B nasal spray four times per day as a treatment of Adjustment Disorder with Anxiety symptoms in adults.
- Trial name
- NCT04404192
- Testing
- PH94B
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- VistaGen Therapeutics, Inc.
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Post-traumatic Stress Disorder, Adjustment Disorders
Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms
The aim of this study is to evaluate the efficacy of SAt-014, a software as a medical device (SaMD), in alleviating symptoms of trauma and stressor-related disorders in patients with post-traumatic stress disorder (PTSD) or…
- Trial name
- NCT06734858
- Testing
- SAT014, Control
- Where
- 5 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- S-Alpha Therapeutics, Inc.
Anxiety, Neurasthenia
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety…
- Conditions
- Anxiety, Neurasthenia, Adjustment Disorders
- Trial name
- NCT06843044
- Testing
- Ranquilon, Afobazole
- Where
- 6 sites in Russia
- Volunteers
- 250 people
- Sponsor
- Valenta Pharm JSC
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Autism Spectrum Disorder, Social Communication Disorder
To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD
The purpose of this study is to demonstrate the superiority of the treatment of cognitive therapy software 'NDTx-01' compared to TAU (Treatment-As-Usual).
- Trial name
- NCT06446193
- Testing
- NDTx-01, TAU
- Where
- 5 sites in South Korea
- Volunteers
- 86 people
- Sponsor
- Neudive Inc.
Parenting Practices, Self Efficacy
Evaluation Study of Talk Parenting Skills
After development of the prototype Bedtime Routine module of the Talk Parenting program, the investigators will evaluate its feasibility and initial efficacy in a within-subjects pre-post design study.
- Conditions
- Parenting Practices, Self Efficacy, Stress, Child Behavior
- Trial name
- NCT04633434
- Testing
- The Talk Parenting Skill for Alexa
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
First Episode Schizophrenia, Social Function
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients
- Conditions
- First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin
- Trial name
- NCT03784222
- Testing
- Blonanserin, MRI and serum BDNF
- Where
- 8 sites in China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Anxiety, Neurasthenia
A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders
The primary objective of the study is to evaluate the efficacy of Ranquilon, 1 mg tablets, at a dose of 6 mg/day compared to placebo for the treatment of patients with anxiety in neurasthenia and adjustment disorder.
- Conditions
- Anxiety, Neurasthenia, Adjustment Disorders
- Trial name
- NCT05586789
- Testing
- Ranquilon
- Where
- 10 sites in Russia
- Volunteers
- 220 people
- Sponsor
- Valenta Pharm JSC
Emotional Adjustment, Mood Disturbance
Digital Health for Caregivers Emotional and Self-management Support
This feasibility study builds upon mental health and technology acceptance theoretical frameworks. It seeks to examine potentials of a novel mobile Health (mHealth) solution based on emotional and behavioral change techniques, to…
- Trial name
- CARING (NCT04812665)
- Testing
- mHealth solution based on emotional and behavioral change techniques
- Where
- Spain
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Hydrocephalus Shunt (proGAV) Requiring Adjustment
X-Ray Verified Accuracy of the proGAV Verification Instrument
This study is to verify the use of a hand held tool to verify the new setting of a hydrocephalus shunt (proGAV). This tool would be used in place of an Xray of the patient's head, which is how settings are verified currently.
- Trial name
- X-AMIN (NCT01885468)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aesculap, Inc.
Schizophrenia
Subjective Well Being of Schizophrenic Patients in Greece
Non-interventional study aiming to provide data on the subjective effects of antipsychotic medication assessing subjective well-being and global functioning of patients with Schizophrenia under antipsychotic medication.
- Trial name
- AURA (NCT00857064)
- Where
- 24 sites in Greece
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Cross - Sectional study requiring one visit at the investigators office for the data collection. Target Group: Patients that suffer from Bipolar Disorder Type 1.
- Trial name
- DIDAXI (NCT00691353)
- Where
- 20 sites in Greece
- Volunteers
- 540 people
- Sponsor
- AstraZeneca